These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18558435)

  • 1. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes.
    Carlsson L
    Pharmacol Ther; 2008 Aug; 119(2):160-7. PubMed ID: 18558435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo models for testing arrhythmogenesis in drugs.
    Carlsson L
    J Intern Med; 2006 Jan; 259(1):70-80. PubMed ID: 16336515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias.
    Thomsen MB; Matz J; Volders PG; Vos MA
    Pharmacol Ther; 2006 Oct; 112(1):150-70. PubMed ID: 16714061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early clinical development: evaluation of drug-induced torsades de pointes risk.
    Vik T; Pollard C; Sager P
    Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
    Gintant GA
    Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation.
    Wang D; Patel C; Cui C; Yan GX
    Pharmacol Ther; 2008 Aug; 119(2):141-51. PubMed ID: 18423604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K
    Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N; Authier S; Pugsley MK; Curtis MJ
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK; Hancox JC; Curtis MJ
    Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the rabbit with a failing heart to test for torsadogenicity.
    Hamlin RL; Kijtawornrat A
    Pharmacol Ther; 2008 Aug; 119(2):179-85. PubMed ID: 18691764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL; Kung MF
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The canine model with chronic, complete atrio-ventricular block.
    Oros A; Beekman JD; Vos MA
    Pharmacol Ther; 2008 Aug; 119(2):168-78. PubMed ID: 18514320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
    Wang WQ; Robertson C; Dhalla AK; Belardinelli L
    J Pharmacol Exp Ther; 2008 Jun; 325(3):875-81. PubMed ID: 18322148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC; McPate MJ; El Harchi A; Zhang YH
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
    Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
    Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.